超选择性动脉内重复输注西妥昔单抗治疗初诊胶质母细胞瘤
超选择性动脉内重复输注西妥昔单抗治疗初诊胶质母细胞瘤的I/II期试验
Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the most common form of primary brain cancer, afflicting approximately 7,000 patients in the United States each year. These highly malignant cancers remain a significant unmet clinical need in oncology. GBM often has a high expression EFGR (Epidermal Growth Factor Receptor) which is blocked by Cetuximab (CTX). The investigators have recently completed a separate Phase I clinical trial using superselective intra-arterial cerebral infusion (SIACI) of CTX after blood brain barrier disruption (BBBD) for recurrent GBM (Chakraborty et al, in revision, Journal of Neurooncology). The investigators found that intra-arterial infusion of CTX is well tolerated with few adverse effects. The investigators hypothesize that in patients with newly diagnosed GBM, repeated SIACI of this drug after BBBD will be safe and efficacious for our patients when combined with standard chemoradiation (STUPP protocol).
This trial will be a non-randomized open label Phase I/II clinical trial. In addition to standard chemotherapy and radiation therapy (STUPP protocol) the patient will be given CTX intra-arterially after BBBD for a total of three doses at approximately post surgery days 30, 120 and 210.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:John Boockvar, MD
- 电话号码:212-434-4836
- 邮箱:jboockvar@northwell.edu
研究联系人备份
- 姓名:Tamika Wong, MPH
- 电话号码:212-434-4836
- 邮箱:twong4@northwell.edu
学习地点
-
-
New York
-
New York、New York、美国、10075
- 招聘中
- Lenox Hill Brain Tumor Center
-
接触:
- Tamika Wong, MPH
- 电话号码:212-434-4836
- 邮箱:twong4@northwell.edu
-
接触:
- John Boockvar, MD
- 电话号码:212-434-3900
- 邮箱:jboockvar@northwell.edu
-
副研究员:
- David Langer, MD
-
副研究员:
- Christopher Filippi, MD
-
副研究员:
- Tamika Wong, MPH
-
副研究员:
- Rafael Ortiz, MD
-
副研究员:
- Ashley Ray, NP
-
副研究员:
- Sherese Fralin, NP
-
副研究员:
- Anuj Goenka, MD
-
副研究员:
- Jed Pollack, MD
-
副研究员:
- Karissa Tan, NP
-
副研究员:
- Shamik Chakraborty, MD
-
首席研究员:
- John Boockvar, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Male or female patients of ≥18 years of age.
-
Patients with a documented histologic diagnosis of newly diagnosed glioblastoma multiforme (GBM)
-
Patients with pathology confirmed histologic EGFR overexpression
-
Patients must have at least one confirmed and evaluable tumor site.∗
*A confirmed tumor site is one in which is biopsy-proven. NOTE: Radiographic procedures (e.g., Gd-enhanced MRI or CT scans) documenting existing lesions must have been performed within two weeks of treatment on this research study.
-
Patients must have a Karnofsky performance status ≥70% (or the equivalent ECOG level of 0-2) and an expected survival of ≥ three months.
-
No chemotherapy for two weeks prior to treatment under this research protocol and no external beam radiation for eight weeks prior to treatment under this research protocol.
-
Patients must have adequate hematologic reserve with WBC≥3000/mm3, absolute neutrophils ≥1500/mm3 and platelets ≥100,000/ mm3. Patients who are on Coumadin must have a platelet count of ≥150,000/ mm3
-
Pre-enrollment chemistry parameters must show: bilirubin<1.5X the institutional upper limit of normal (IUNL); AST or ALT<2.5X IUNL and creatinine<1.5X IUNL.
-
Pre-enrollment coagulation parameters (PT and PTT) must be ≤1.5X the IUNL.
-
Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study.
-
Patients must be able to understand and give written informed consent. Informed consent must be obtained at the time of patient screening.
Exclusion Criteria:
- Women who are pregnant or lactating.
- Women of childbearing potential and fertile men will be informed as to the potential risk of conception while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period.
- Patients with significant intercurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring
- Patients with radiological evidence of leptomeningeal disease.
- Patients with history of allergic reaction to CTX
- Patients who initiated or completed chemo/RT
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Intra-arterial Cetuximab after BBBD
Mannitol 20% 12.5ml over two minutes for Blood Brain Barrier (BBB) disruption followed by CTX administered intra-arterially for three doses at a dose of 250mg/m2 |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression Free Survival (PFS)
大体时间:6 months
|
The 6-month PFS will be estimated by calculating the proportion of patients who are alive at 6 months from treatment commencement and are progression-free. |
6 months
|
|
Overall Survival (OS)
大体时间:2 years
|
OS will be calculated as the time from treatment initiation to the date of death. |
2 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Composite overall response rate (CORR) through the Response Assessment in Neuro-Oncology (RANO)
大体时间:6 months
|
Subjects will be classified according to the RANO criteria, which is a composite of MRI changes, clinical response and changes in steroid use. |
6 months
|
|
Toxicities graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03
大体时间:6 months
|
Toxicities will be tabulated and graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03 |
6 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.